Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

September 30, 2018

Study Completion Date

March 31, 2019

Conditions
Renal Insufficiency, Chronic
Interventions
DRUG

Ramipril

Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.

DRUG

placebo to ramipril

Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.

DRUG

Ramipril

Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.

Trial Locations (1)

37075

University Medical Center Goettingen, Göttingen

All Listed Sponsors
collaborator

University Medical Center Goettingen

OTHER

collaborator

German Federal Ministry of Education and Research

OTHER_GOV

lead

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

OTHER

NCT01485978 - Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome | Biotech Hunter | Biotech Hunter